In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4+ cells was below normal up to 6 months post-transplant, while the absolute number remain low throughout the first year. The CD8+ percentage and absolute numbers remain normal at all times post-transplant. The CD19+ cells were also normal post-transplantation. The mitogen lymphocyte stimulation was normal in 27 out of 31 patients tested after 6 months post-transplant. Our analysis of immune reconstitution shows a similar pattern to previous studies with a faster recovery of the CD4/CD8 ratio, especially in those patients who did not receive TBI. In conclusion, the observed deficiencies are transient and have very little clinical significance because, historically, the rate of serious infections is low despite prolonged immune suppression. The recovery postautologous transplant is fast.
Summary:
In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4+ cells was below normal up to 6 months post-transplant, while the absolute number remain low throughout the first year. The CD8+ percentage and absolute numbers remain normal at all times post-transplant. The CD19+ cells were also normal post-transplantation. The mitogen lymphocyte stimulation was normal in 27 out of 31 patients tested after 6 months post-transplant. Our analysis of immune reconstitution shows a similar pattern to previous studies with a faster recovery of the CD4/CD8 ratio, especially in those patients who did not receive TBI. In conclusion, the observed deficiencies are transient and have very little clinical significance because, historically, the rate of serious infections is low despite prolonged immune suppression. The recovery postautologous transplant is fast. Bone Marrow Transplantation (2003) 31, 285-290. doi:10.1038/sj.bmt.1703831 Keywords: autologous; stem cell transplantation; immune reconstitution Autologous hematopoietic stem cell or bone marrow transplantation following myeloablative therapy is an established treatment option for high-risk malignancies of childhood including lymphoma, solid tumors, and, in some instances, leukemia. However, a period of immunodeficiency following the transplant puts the patient at risk for life-threatening infections.
1
The kinetics of immune reconstitution following various modes of transplant have been previously studied and found to be impaired for up to several years. Studies have shown that immune reconstitution is accelerated following autologous transplant when compared to allogeneic transplant.
2-4
In the allogeneic setting, graft-versus-host disease (GVHD) and immune-suppressive therapy may interfere with recovery of the immune system, and autologous transplant offers a different opportunity to study physiologic regeneration.
Most of the studies showing delayed immune reconstitution, however, have focused on adults 3,5,6 and only a few authors have looked at immune reconstitution after autologous transplantation in children. [7] [8] [9] In this study, immune reconstitution was analyzed retrospectively in 58 children who had undergone either autologous peripheral blood stem cell or bone marrow transplantation for varying malignancies, including neuroblastoma (NBL), leukemia and solid tumors. In these patients we evaluated recovery of T-cell subsets, B cells, natural killer (NK) cells, immunoglobulin levels, and response to mitogen stimulation for up to 1 year following transplant.
Patients and methods

Patients
Between March 1992 and Febuary 2000, 125 patients underwent autologous transplantation at Children's Memorial Hospital, Chicago, IL. Of these patients, six died too soon after transplant to be evaluated and a further 61 patients could not be included because lack of consistent follow-up laboratory data. A total of 58 patients (24 female, 34 male) were studied retrospectively for immune reconstitution following autologous transplant for the following diseases: high-risk NBL n ¼ 22, ANLL n ¼ 7, ALL n ¼ 6, Wilm's tumor n ¼ 5, rhabdomyosarcoma n ¼ 5, Hodgkin's disease n ¼ 4, NHL n ¼ 3, Ewing's sarcoma n ¼ 2, high-grade glioma n ¼ 1, myelodysplastic syndrome (MDS) n ¼ 1, medulloblastoma n ¼ 1, and soft tissue sarcoma n ¼ 1. The average age was 8.2 years, with a median of 6.3 years (range 0.5-23.4). Prior to transplant patients received ablative regimens consisting of either high-dose chemotherapy with total body irradiation (TBI) (n ¼ 10) or high-dose chemotherapy alone (n ¼ 48) (Table 1) . Following this treatment, the autograft was reinfused. Of the patients studied, 43 received unmanipulated peripheral blood stem cells (PBSC), and 15 received bone marrow. A total of 48 patients received one transplant, one patient received two, and nine patients received three tandem transplants. The details of PBSC harvest, BM harvesting, and processing and cryopreservation of cells have been described previously. 10, 11 The grafts from two patients with ANLL and the patient with MDS were purged with 4-hydroperoxycyclophosphamide. 12 The stem cells from a single patient with ALL were purged using immunomagnetic beads. 13 Immunologic and hematologic reconstitution was monitored post-transplant for 1 year.
Supportive care
Patients were routinely treated in a hepa-filtered unit. Acyclovir and fluconazole were given prophylactically to all patients. IVIG (250 mg/kg) was given weekly from day À1 until a minimum of Day 60 to 46 patients. These patients were excluded from analysis of IgG levels for 4 weeks following their last dose of IVIG. Parenteral antibiotics were used empirically for treatment of fever and neutropenia, and modified as appropriate for bacterial isolates. The majority of patients received G-CSF or GM-CSF postinfusion until they had achieved an ANC45000/ml.
Flow cytometry
Immunophenotyping of peripheral blood cells was performed using flow cytometry. Briefly, whole blood samples obtained from the patients were stained with fluorochromelabeled antibodies that bind specifically to leukocyte surface antigens. The stained samples were treated with FACS lysing solution to lyse erythrocytes and then run on a FACScan or FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Automated sample acquisition and analysis were performed using Simultest software (Becton Dickinson, San Jose, CA, USA), which identifies the lymphocytes according to forward-and rightangle light scatter parameters as well as characteristics of CD45 expression. The following premixed two-color monoclonal antibody combinations were used to identify specific lymphocyte subsets: CD45-FITC/CD14-PE (lymphocyte gating reagent), CD3-FITC/CD4-PE (T-helper 
Immunoglobulin levels
Serum IgG levels were measured using a Beckman ARRAY standard nephelometer.
Lymphocyte stimulation assay
Lymphocyte proliferative responses were determined by exposing isolated peripheral blood mononuclear cells (PBMC) to the mitogens phytohemagglutinin, concanavalin A, and pokeweed mitogen. Briefly, PBMC were separated from patient whole blood samples by density gradient centrifugation and then resuspended in RPMI (Gibco, Gaithersberg, MD, USA) supplemented with penicillin/streptomycin, l-glutamine and fetal bovine serum. Cells (1 Â 10 5 per well) were cultured in 96-well flatbottom plates with optimal concentrations of phytohemagglutinin (Mirex, Abbott Park, IL, USA), pokeweed mitogen (Gibco, Gaithersberg, MD, USA), or concanavalin A (Pharmacia, Kalamazoo, MI, USA) for 3 days at 371C under 5% CO 2 . At 4 h before harvesting, cells were pulsed with 3 H-labeled thymidine (ICN, Urvine, CA, USA) (1 uCi/well). Cells were harvested with a Skatron cell harvester. Radioactivity was measured in a liquid scintillation counter (Beta Plate, Perkin Elmer, Gaithersberg, MD, USA) and expressed as a stimulation index by dividing the counts per minute (cpm) in the stimulated samples by the cpm in the unstimulated samples. The results were interpreted as consistent with normal or below normal.
Statistical analysis
Statistical analysis including unpaired t-tests was performed using the software program Prism* (Graphpad Software Inc., San Diego, CA, USA) to compare values between different subgroups.
Results
Hematopoietic recovery
The median mononuclear cell dose infused was 2.0 Â 10 8 /kg with a mean of 2.6 and a range of 0.23-28. The median time to an ANC 4500/ml was 14 days (range 6-62). The median time to a sustained platelet count of greater than 20 Â 10 9 /l without transfusion was 23 days (range 6-210). Immune reconstitution after autologous transplants in children S Hoepfner et al
Lymphocyte subset recovery
As a result of the small patient numbers and irregular follow up, we chose to group the data in two time ranges: results up to 6 months after transplant, and between 6 and 12 months after transplant. The median percentage of CD3+ cells was below normal up to 6 months post-transplant, but thereafter returned to normal (Figure 1) . The absolute numbers of CD3+ cells did not reach the normal range during the first year after transplant, with only 50% of the patients showing values above 1018/ml between 6 and 12 months ( Table 2) . The median percentage of CD4+ cells was below normal up to 6 months post-transplant before reaching a normal level 1-year post-transplant (Figure 2) . The absolute number of CD4+ cells remained low throughout the first year after transplant. The absolute number of CD8+ was below normal for up to 6 months, but thereafter returned to the normal range. The median percentage of CD8+ cells was within normal limits at all evaluated time points, as was the CD4/CD8 ratio ( Figure 3) . Over 60% of patients had normal ratios for both time ranges analyzed. The median percentage of CD19+ cells was persistently above normal in the first year following transplant, whereas the absolute number remained normal. The median percentage of NK cells was normal at all time points studied post-transplant, but the absolute number was always decreased. The median percentage of DR cells was above the normal range throughout the first year post-transplant, with absolute numbers being low for up to 6 months and then returning to normal.
Immunoglobulin levels
Median levels of IgG were normal during the first month following transplant and remained normal during the first year post-ransplant (Table 3) .
Lymphocyte proliferative responses
Six months after transplant, only two out of six patients tested had normal responses to mitogens. Of the 31 patients tested between 6 and 12 months posttransplant, 27 had responses consistent with normal ( Figure 4 ).
Subgroups
The following subgroups were compared to each other to evaluate the influence of various factors on immune Immune reconstitution after autologous transplants in children S Hoepfner et al reconstitution: patients with NBL vs patients with leukemia, patients who had been treated with TBI vs chemotherapy alone, patients who had received three transplants vs only one, and patients who had received PBSC vs bone marrow cells.
Significant P-values were found when comparing the group who had received TBI to those who had been treated with chemotherapy alone. The TBI group had a significantly lower CD4/CD8 ratio, a higher absolute number of CD8+ cells, and a higher absolute number of DR cells between 6 and 12 months after transplant (Table 4 ). Another significant difference was found between the patients who had received three stem cell transplants vs only one. The IgG level between 6 and 12 months after transplant was higher for the patients who had been treated with one transplant, and the CD4/CD8 ratio was significantly lower in this group (Table 5) . Furthermore, the patients with leukemia (n ¼ 11) had a significantly higher absolute number of CD8+ cells (P ¼ 0.04) than the patients with NBL (n ¼ 15) (data not shown).
Discussion
We have analyzed immune reconstitution following autologous stem cell transplantation in children, and found a delay of up to 1 year in the complete recovery of the T-cell subsets and their function. Given the intensive ablation therapy that precedes the reinfusion of PBSC or bone marrow, this is not unexpected. Cyclophosphamide, which was included in most of the regimens used here, is well known to induce immunosuppression even when used as part of a treatment protocol not including transplant. 14, 15 TBI has been shown to lead to delay in immune reconstitution in animal studies. 8, 16 A number of studies looking at immune reconstitution following transplant in adults have found a consistent pattern of more rapid recovery of CD8+ cells than CD4+ cells, resulting in a low CD4/CD8 ratio ranging from months to years after transplant.
5, [17] [18] [19] [20] [21] [22] Several studies have also evaluated the influence of allogeneic vs autologous transplant and PBSC vs bone marrow as source of graft on immune reconstitution. These have shown that although the general pattern of lymphocyte recovery seems to be similar regardless of graft source, immune reconstitution tends to occur faster after PBSC transplant than after bone marrow. 3, 17, 23, 24 One study does report similar kinetics in both groups. 19 Regarding the comparison between autologous and allogeneic grafts, several studies have shown no significant difference.
3,25
Only a few studies have evaluated immune reconstitution following autologous transplant in children. Similar to our results, these report decreased levels of CD4+ cells after transplant for up to 12 months and normal or elevated levels of CD8+ cells. 8, 9, 26 The regeneration of CD4+ cells seems to be dependant on a thymic pathway as well as peripheral expansion of mature CD4+ cells.
14 Age-associated thymic involution restricts the thymic pathway and may be responsible for prolonged depletion in older children and adults. The recovery of CD4+ cells has been shown to be inversely correlated to age. 7 No such relation has been found for recovery of CD8+ cells. 27 This results in a decreased CD4/CD8 ratio, which in two previous studies done in children after autologous bone marrow transplant has been found to persist 12 months or longer. 8, 9 We found normal values for the CD4/CD8 ratio as early as 6 months after transplant. This could possibly be explained by the fact that the majority of the patients in our study received PBSCs, which have been reported to result in faster Immune reconstitution after autologous transplants in children S Hoepfner et al recovery than bone marrow, as mentioned above. The significant difference between the CD4/CD8 ratio in patients who had received ablation regimens containing TBI vs chemotherapy alone is most likely an indicator of the higher degree of toxicity of radiation. At this point, the reason for the higher CD4/CD8 ratio in patients who had been treated with three transplants rather than only one seems unclear and is likely be related to small patient numbers.
The finding of normal absolute levels of B cells and elevated percentages following transplant have also been previously reported. 7, 8 Most studies have observed rapid recovery of NK cells 7,8 just as we saw normal percentages following transplant. The low absolute number of NK cells we observed may simply reflect the absolute lymphopenia represented by the low absolute number of CD3+ cells persisting throughout the first year after transplant. Previous studies have also shown that reappearing NK cells may simply reflect the absolute lymphopenia functionally impaired, 7, 28 and this prompt recovery may very well be clinically significant because of their ability to provide defense against infection and possibly persisting tumor cells.
2,29
Contradictory results exist regarding the serum levels of IgG and range from normal after transplant to low levels for over 12 months.
7, 8 Although we found normal median levels in the entire patient group, the serum IgG was significantly higher in those patients who had been treated with three subsequent transplants vs only one. This most likely reflects the more intensive therapy involved in multiple transplants and may imply that these patients would profit from longer treatment with IVIG following their transplant.
We found elevated levels of cells that express DR after transplant, which has been reported previously in children as well as in adults, 21, 26, 30 although the clinical significance of this is unknown. 21, 31 In summary, our analysis of immune reconstitution showed a similar overall pattern to previous studies with a faster recovery of the CD4/CD8 ratio, especially in patients who had not received TBI. Although we did not take into account the infectious complications that occurred during the post-transplant period, other authors have recorded no serious infections despite prolonged immune suppression. 8 It seems that the observed deficiencies are transient and are followed by a relatively reliable pattern of recovery. This may imply that it is unnecessary to regularly monitor immune parameters such as lymphocyte subsets and proliferation responses unless required by clinical signs of prolonged immune deficiency.
It is to be kept in mind that the retrospective approach and relatively small patient numbers, as well as the heterogeneous regimens of immune ablation and demographic parameters, limited our study. This seems to suggest the need for a large prospective study including precise documentation of infectious complications and their correlation with immune suppression. However, the failure of previous studies to show major clinical implications may not warrant this approach. Immune reconstitution after autologous transplants in children S Hoepfner et al
